# Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular

> **NCT03322657** · PHASE4 · COMPLETED · sponsor: **The Cleveland Clinic** · enrollment: 69 (actual)

## Conditions studied

- Neuromuscular Blockade
- Anesthesia

## Interventions

- **DRUG:** Neostigmine
- **DRUG:** Glycopyrrolate
- **DRUG:** Sugammadex

## Key facts

- **NCT ID:** NCT03322657
- **Lead sponsor:** The Cleveland Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-14
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-02-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03322657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03322657, "Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03322657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*